These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35404425)

  • 1. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation.
    Caravaca-Fontán F; Polanco N; Villacorta B; Buxeda A; Coca A; Ávila A; Martínez-Gallardo R; Galeano C; Valero R; Ramos N; Allende N; Cruzado-Vega L; Pérez-Sáez MJ; Sevillano Á; González E; Hernández A; Rodrigo E; Fernández-Ruiz M; Aguado JM; Pérez Valdivia MÁ; Pascuall J; Andrés A; Praga M;
    Nephrol Dial Transplant; 2023 Jan; 38(1):222-235. PubMed ID: 35404425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification.
    Alasfar S; Carter-Monroe N; Rosenberg AZ; Montgomery RA; Alachkar N
    BMC Nephrol; 2016 Jan; 17():7. PubMed ID: 26754737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.
    Wilson GJ; Cho Y; Teixiera-Pinto A; Isbel N; Campbell S; Hawley C; Johnson DW
    BMC Nephrol; 2019 Nov; 20(1):417. PubMed ID: 31752734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Sep; 39(9):2679-2689. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
    Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
    Noris M; Daina E; Remuzzi G
    Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
    Von Visger J; Cassol C; Nori U; Franco-Ahumada G; Nadasdy T; Satoskar AA
    BMC Nephrol; 2019 Feb; 20(1):53. PubMed ID: 30764798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membranoproliferative glomerulonephritis: current histopathological classification, clinical profile, and kidney outcomes.
    Bernardes TP; Mastroianni-Kirsztajn G
    J Bras Nefrol; 2023; 45(1):45-50. PubMed ID: 35789244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].
    Rudnicki M; Windpessl M; Eller K; Odler B; Gauckler P; Neumann I; Zitt E; Regele H; Kronbichler A; Lhotta K; Säemann MD
    Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):688-695. PubMed ID: 37728653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival.
    de Paula LC; Mazzali M; de Sousa MV
    Ann Transplant; 2023 Jul; 28():e940502. PubMed ID: 37461201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
    Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics and outcomes of adult patients with idiopathic membranoproliferative glomerulonephritis according to an immunofluorescence-based classification.
    Elahi T; Ahmed S; Ahmed E; Mubarak M
    J Nephrol; 2024 Nov; 37(8):2255-2265. PubMed ID: 39400860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection.
    Völker LA; Burkert K; Scholten N; Grundmann F; Kurschat C; Benzing T; Hampl J; Becker JU; Müller RU
    BMC Nephrol; 2019 Aug; 20(1):296. PubMed ID: 31382904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.
    Patry C; Webb NJA; Feißt M; Krupka K; Becker J; Bald M; Antoniello B; Bilge I; Gulhan B; Hogan J; Kanzelmeyer N; Ozkaya O; Büscher A; Sellier-Leclerc AL; Shenoy M; Weber LT; Fichtner A; Höcker B; Meier M; Tönshoff B
    Pediatr Nephrol; 2024 Dec; 39(12):3569-3580. PubMed ID: 39110227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.
    Nakano M; Karasawa K; Moriyama T; Uchida K; Nitta K
    Clin Exp Nephrol; 2019 Jun; 23(6):852-858. PubMed ID: 30854618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis.
    Angelo JR; Bell CS; Braun MC
    Am J Kidney Dis; 2011 Feb; 57(2):291-9. PubMed ID: 21215503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.